欢迎您注册蒲公英
您需要 登录 才可以下载或查看,没有帐号?立即注册
x
What are "complex manufacturing processes"? A recent reply from the EMA 什么是“复杂生产工艺:?EMA最近给出回答 欧洲委员会的“变更规定(EC)1234/2008”中定义了已有上市许可的变更程序。欧洲官方杂质上于2013年8月公布了“变更分类详细指南”整体更新版本,其中解释了该变更规定的应用和诠释。 尽管“详细指南”详细描述了大量的可能变更情景,在指南正文中有一些公式,但有些模糊需要澄清。EMA在最近对其“问答集合“药品质量问答:第1部分””更新中采用了这样一个案例,以在整个声明中具体说明该案例。 It is about the term "complex manufacturing processes", which is used in two scenarios associated with type II variations (found in the "detailed guidelines" p 40ff): 这是一个关于术语“复杂生产工艺”的案例,它用在两个关于二类变更的案例(页40ff的“详细指南”) - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product (Guideline change code B.II.b.1) 部分或全部药品生产工艺变更或增加一个生产场所
...
c) Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/immunological medicinal products, or for pharmaceutical forms manufactured by complex manufacturing processes. 微生物/免疫药品,或以下产品,除批放行、批检验和外包装以外的所有生产操作发生的场所, - Change in the batch size (including batch size ranges) of the finished product (Guideline change code B.II.b.4) 制剂(指南变更代码B.II.b.4)批量变更(包括批量范围)
...
d) The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes . 与所有用复杂生产工艺生产的其它药品剂型有关的变更
The EMA now clarified this term as follows: EMA现在澄清此术语如下: - Guideline Change Code B.II.b.1: Complex manufacturing processes are given when the understanding of the relation between quality characteristics of the product and its in vivo efficacy is lacking. This is often the case in innovative medicines such as products of nanomedicine.
- 指南变更代码B.II.b.1:在缺乏产品质量属性和其体内有效性之间的关系知识时,要定义为复杂生产工艺。通常非创新药,例如纳米医学产品就是这样。
- Guideline Change Code B.II.b.4: Complex manufacturing processes are those which contain one or more sub-steps, where a scale-up can lead to problems.
- 指南变更代码B.II.b.4:复杂生产工艺是指那些包括一个或多个子步骤的工艺,放大生产可能会产生问题。
In both scenarios, the approving authority will decide on a case by case basis. If the applicant submits the variation as a Type IB, he must provide a valid justification that the production process is not "complex". However, in doubt the authority may upgrade the variation to a Type II. Therefore, the EMA recommends that the applicant clarifies the situation with the authority before submitting the variation. 在两种情形下,负责批准的药监部门要根据实际案例来做出决定。如果申报者作为IB类变更提交,则必须提交有效的论述,证明生产工艺并不“复杂”。但是,如果药监当局有疑问的话,可能会将其升级为II类变更,因此EMA建议申报者在提交变更之前,提前与药监当局就实际情况进行澄清。 |